Big Pharma’s Patent Abuse and Impact on Healthcare Costs

In the past few years, a significant worry for many Americans has been the rising cost of healthcare. A major contributing factor to this surge is Big Pharma’s patent abuse, which has led to an increase in healthcare costs by over $40 billion in just one year. This article aims to dissect the role of Big Pharma in escalating healthcare costs and explores the need for lawmakers to hold brand name drug manufacturers accountable and put an end to their anti-competitive tactics.

The Impact on Texas

An article in the Houston Chronicle highlights the rising healthcare costs in Texas, with the spotlight on the abuse of patents by pharmaceutical companies. Particularly, the prices for arthritis drugs Enbrel and Humira, as well as the diabetes drug Trulicity have seen a significant increase. Moreover, these companies have found ways to extend their patents beyond the permitted 20 years, leading to a lack of competition and the absence of cheaper generic alternatives. The article strongly advocates for Congress to reform the patent process to prevent the health of Texans from being compromised for financial gain.

Big Pharma’s Anti-Competitive Tactics

Pharmaceutical companies have employed anti-competitive tactics including patent abuse and price gouging, leading to an astonishing cumulative increase of 295.5% in drug prices from 2006 to 2020. This has resulted in reduced accessibility to essential medications and a significant strain on patients, taxpayers, and the U.S. healthcare system. The consequences of high drug prices are felt most acutely by patients who cannot afford necessary medications, leading to a growing bipartisan call for reform to address the root causes of high drug prices.

Effects on Rural Areas

Big Pharma’s unethical tactics are also keeping healthcare costs high in rural areas like South Carolina. Over 30% of South Carolinians live in rural communities and 6 in 10 suffer from one or more chronic illnesses. Big Pharma is accused of exploiting legal loopholes to hijack patent and regulation systems, using ‘product hopping’ and ‘pay-for-delay’ tactics to keep competition off the market. This has resulted in many residents being unable to afford necessary medications, thereby highlighting the disparities faced by rural counties due to lack of access to healthcare and prescription drugs.

Need for Policy Changes

Pharmaceutical companies’ abuse of patents leads to monopolies on certain drugs, resulting in high prices and limited access for patients. This issue calls for policy changes to ensure affordable healthcare for all. Big Pharma companies like Johnson & Johnson have been hiking drug prices above the rate of inflation and have been accused of waiting to introduce new products until they can get approval for more lucrative disease classes. They have also been discredited for their rhetoric on research and development and faced criticism for tax avoidance schemes and the use of kickbacks to boost profits.

In conclusion, Big Pharma’s patent abuse and anti-competitive tactics have a substantial role in the escalating healthcare costs. It is high time that lawmakers and regulatory bodies take robust action to reform the patent system, increase transparency, foster competition, and promote value in the pharmaceutical industry. Only by addressing these issues can we ensure that the health of the public is not compromised for financial gain.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source